Annual Cash & Cash Equivalents
$271.77 M
+$43.95 M+19.29%
December 31, 2023
Summary
- As of February 8, 2025, VRNA annual cash & cash equivalents is $271.77 million, with the most recent change of +$43.95 million (+19.29%) on December 31, 2023.
- During the last 3 years, VRNA annual cash & cash equivalents has risen by +$83.79 million (+44.57%).
- VRNA annual cash & cash equivalents is now at all-time high.
Performance
VRNA Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$336.04 M
-$68.56 M-16.94%
September 30, 2024
Summary
- As of February 8, 2025, VRNA quarterly cash and cash equivalents is $336.04 million, with the most recent change of -$68.56 million (-16.94%) on September 30, 2024.
- Over the past year, VRNA quarterly cash and cash equivalents has dropped by -$68.56 million (-16.94%).
- VRNA quarterly cash and cash equivalents is now -16.94% below its all-time high of $404.60 million, reached on June 30, 2024.
Performance
VRNA Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
VRNA Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +19.3% | -16.9% |
| 3 y3 years | +44.6% | +101.8% |
| 5 y5 years | +982.6% | +708.3% |
VRNA Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +83.2% | -16.9% | +201.3% |
| 5 y | 5-year | at high | +793.2% | -16.9% | +1409.9% |
| alltime | all time | at high | >+9999.0% | -16.9% | >+9999.0% |
Verona Pharma Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $336.04 M(-16.9%) |
| Jun 2024 | - | $404.60 M(+58.7%) |
| Mar 2024 | - | $254.88 M(-6.2%) |
| Dec 2023 | $271.77 M(+19.3%) | $271.77 M(+5.6%) |
| Sep 2023 | - | $257.37 M(-4.9%) |
| Jun 2023 | - | $270.73 M(-7.1%) |
| Mar 2023 | - | $291.42 M(+27.9%) |
| Dec 2022 | $227.83 M(+53.5%) | $227.83 M(-1.7%) |
| Sep 2022 | - | $231.70 M(+107.8%) |
| Jun 2022 | - | $111.51 M(-16.0%) |
| Mar 2022 | - | $132.76 M(-10.5%) |
| Dec 2021 | $148.38 M(-21.1%) | $148.38 M(-10.9%) |
| Sep 2021 | - | $166.55 M(+14.0%) |
| Jun 2021 | - | $146.03 M(-13.9%) |
| Mar 2021 | - | $169.60 M(-9.8%) |
| Dec 2020 | $187.99 M(+517.8%) | $187.99 M(-6.9%) |
| Sep 2020 | - | $201.97 M(+807.5%) |
| Jun 2020 | - | $22.26 M(-10.3%) |
| Mar 2020 | - | $24.81 M(-18.5%) |
| Dec 2019 | $30.43 M(+21.2%) | $30.43 M(-26.8%) |
| Sep 2019 | - | $41.58 M(+46.2%) |
| Jun 2019 | - | $28.43 M(+16.4%) |
| Mar 2019 | - | $24.42 M(-2.7%) |
| Dec 2018 | $25.10 M(-40.9%) | $25.10 M(-30.1%) |
| Sep 2018 | - | $35.91 M(-24.9%) |
| Jun 2018 | - | $47.82 M(+17.6%) |
| Mar 2018 | - | $40.66 M(-4.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2017 | $42.49 M(-13.4%) | $42.49 M(+1.0%) |
| Sep 2017 | - | $42.06 M(-48.4%) |
| Jun 2017 | - | $81.46 M(+66.0%) |
| Dec 2016 | $49.09 M(+840.1%) | $49.09 M(+2950.0%) |
| Jun 2016 | - | $1.61 M(-69.2%) |
| Dec 2015 | $5.22 M(-66.4%) | $5.22 M(-45.5%) |
| Jun 2015 | - | $9.58 M(-38.2%) |
| Dec 2014 | $15.52 M(+1458.6%) | $15.52 M(-24.7%) |
| Jun 2014 | - | $20.61 M(+1969.9%) |
| Dec 2013 | $995.60 K(-35.9%) | $995.60 K(-29.6%) |
| Jun 2013 | - | $1.41 M(-8.9%) |
| Dec 2012 | $1.55 M(-60.4%) | $1.55 M(-58.0%) |
| Jun 2012 | - | $3.70 M(-5.6%) |
| Dec 2011 | $3.92 M(+26.9%) | $3.92 M(+112.2%) |
| Jun 2011 | - | $1.85 M(-40.2%) |
| Dec 2010 | $3.09 M(-32.4%) | $3.09 M(-29.4%) |
| Jun 2010 | - | $4.38 M(-4.4%) |
| Dec 2009 | $4.58 M(+27.3%) | $4.58 M(+66.3%) |
| Jun 2009 | - | $2.75 M(-23.4%) |
| Dec 2008 | $3.60 M(+44.8%) | $3.60 M(-42.9%) |
| Jun 2008 | - | $6.30 M(+153.8%) |
| Dec 2007 | $2.48 M(+19.2%) | $2.48 M(-33.4%) |
| Jun 2007 | - | $3.73 M(+78.9%) |
| Dec 2006 | $2.08 M(+23.3%) | $2.08 M(+30.6%) |
| Jun 2006 | - | $1.59 M(-5.6%) |
| Dec 2005 | $1.69 M | $1.69 M(-5.8%) |
| Jun 2005 | - | $1.79 M |
FAQ
- What is Verona Pharma annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Verona Pharma?
- What is Verona Pharma annual cash & cash equivalents year-on-year change?
- What is Verona Pharma quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Verona Pharma?
- What is Verona Pharma quarterly cash and cash equivalents year-on-year change?
What is Verona Pharma annual cash & cash equivalents?
The current annual cash & cash equivalents of VRNA is $271.77 M
What is the all time high annual cash & cash equivalents for Verona Pharma?
Verona Pharma all-time high annual cash & cash equivalents is $271.77 M
What is Verona Pharma annual cash & cash equivalents year-on-year change?
Over the past year, VRNA annual cash & cash equivalents has changed by +$43.95 M (+19.29%)
What is Verona Pharma quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of VRNA is $336.04 M
What is the all time high quarterly cash and cash equivalents for Verona Pharma?
Verona Pharma all-time high quarterly cash and cash equivalents is $404.60 M
What is Verona Pharma quarterly cash and cash equivalents year-on-year change?
Over the past year, VRNA quarterly cash and cash equivalents has changed by -$68.56 M (-16.94%)